89 results
ARS
2023 FY
XFOR
X4 Pharmaceuticals Inc
29 Apr 24
Annual report to shareholders
4:58pm
of our competitors may have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing … : the acceptance by the FDA of our first NDA, for which $5.0 million has been paid and expensed as research and development expense. As of December 31, 2023
8-K
EX-99.1
XFOR
X4 Pharmaceuticals Inc
21 Mar 24
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial
7:43am
mavorixafor be approved for WHIM syndrome in the U.S.
Research and Development (R&D) Expenses were $15.3 million and $72.0 million for the fourth … 31,
Operating expenses:
Research and development
Selling, general and administrative
Gain on sale of non-financial asset
Total operating expenses
8-K
EX-99.1
pu6itfdms7h2f9flwp7
9 Nov 23
X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates
8:07am
8-K
EX-99.1
o29b9gkpynne1ykt
10 Aug 23
Provides Corporate Updates, and Reports Emerging Data from
6:41am
424B3
fftfegz
20 Jun 23
Prospectus supplement
5:36pm
8-K
EX-99.1
t2fghvgd1iaph iezva5
4 May 23
X4 Pharmaceuticals Reports First-Quarter 2023 Financial
9:05am
8-K
EX-99.1
tdqgpq st7u
4 May 23
X4 Pharmaceuticals Reports First-Quarter 2023 Financial
6:42am
8-K
EX-99.1
81fivo rv9yc2z2ei1
3 Nov 22
X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:21am
8-K
EX-99.1
u44wlw 50hkxd
4 Aug 22
X4 Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
7:29am